Relay Therapeutics is a clinical-stage precision medicine company that is transforming the drug discovery process by integrating cutting-edge computational and experimental technologies. Based in Cambridge, Massachusetts, Relay Therapeutics is pioneering a new era of drug discovery by unlocking the secrets of protein motion.

Traditional drug discovery is often compared to looking at old black and white photos. Relay Therapeutics, however, has developed an approach that enables them to visualize protein motion in high-definition movies. By leveraging their leading-edge experimental and computational approaches, they aim to more effectively drug targets that have previously been intractable or inadequately drugged.

Relay Therapeutics has its own technology that applies artificial intelligence and machine learning techniques to drug discovery. They have developed a proprietary computational technology that finds ways to drug hard-to-hit protein targets. This technology has led to the discovery and development of several cancer drugs that are currently in early clinical development.

One of their notable developments is RLY-2608, a drug candidate for which they solved the full-length cryo-EM structure of PI3Kα, performed computational long time-scale molecular dynamic simulations to elucidate conformational differences between wild type and mutant PI3Kα, and leveraged these insights to support the design of RLY-2608.